The UK medical cannabis market is one of the fastest-growing regulated channels in Europe, with an estimated 50,000 to 100,000 patients receiving private prescriptions as of early 2026. For Canadian Licensed Producers looking beyond Germany and Australia, the UK is a credible next market. The import pathway is distinct, dual-gated, and documentation-heavy.
What follows is what you need to know before your first conversation with a UK distribution partner: who regulates the import, what documentation your UK buyer needs from you, and why Health Canada GMP is already recognised on the other side of the Atlantic.
How the UK regulates medical cannabis imports
Cannabis-based products for medicinal use (CBPMs) have been legally prescribable in the UK since November 2018 under the Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. CBPMs are classified as Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001. Specialist physicians on the General Medical Council (GMC) register can prescribe them, but commercial handling, including importation, requires specific licences from two separate bodies.
Two regulatory bodies govern the UK import framework.
The Home Office acts as the UK's National Cannabis Agency and issues Controlled Drugs (CD) licences. Any entity in the UK wishing to possess, import, supply, or distribute CBPMs must hold a CD domestic licence. A separate import licence is required per consignment, in addition to the underlying domestic licence. Import licences are valid for three months from issue.
The Medicines and Healthcare products Regulatory Agency (MHRA) issues Wholesale Distribution Authorisations (WDA(H)) and assesses product quality at the point of importation. The MHRA actively monitors CBPM imports and may refuse or delay consignments where documentation or product standards fall short.
From a Canadian LP's perspective, these licensing obligations sit on the UK side. Your UK distribution partner holds both the CD licence and the WDA(H). Your job is to make sure the product you supply meets the quality and documentation standards that allow your partner to secure the import licence and clear MHRA review.
What the UK importer needs from you
Your UK partner can't obtain an import licence without a complete documentation package from you. The MHRA reviews this package as part of its Letter of No Objection to Import (LNOI) process. Without the LNOI, no import licence is issued.
The documentation your UK partner will need from you:
- GMP compliance evidence. The UK requires medicinal cannabis to be manufactured at sites certified to EU Good Manufacturing Practice (EU-GMP) or an equivalent recognised standard. Health Canada GMP is recognised by the MHRA as equivalent. Your certificate must be current and must cover the specific activities in the shipment.
- Certificate of Analysis (COA). A full COA from an ISO/IEC 17025-accredited laboratory must accompany each batch, covering potency (THC, CBD, CBN at minimum), residual solvents, microbials, heavy metals, pesticides, and water activity. Incomplete panel data is one of the most common reasons MHRA holds a shipment.
- Health Canada Export Permit. You must hold a valid per-shipment export permit issued under the Cannabis Act and Cannabis Regulations before each shipment leaves Canada. The Canadian export permit and the UK import licence are paired documents for the consignment.
- GACP certification (preferred; if not held, additional cultivation documentation will be required by your UK partner).
- Batch traceability records tracing each batch back to the cultivation site, harvest, and production record.
- Clinical justification (arranged by your UK partner's clinic or pharmacy; the justification references your specific product, so your product information sheet must be accurate and complete).
The 6-step Canada-UK supply path
The compliance sequence for a first shipment from a Canadian LP into the UK medical channel follows a consistent pattern. Working through each step before approaching the border prevents the most common delays.
Step 1: Identify and qualify your UK distribution partner. The partner must hold an active CD domestic licence and a WDA(H). Confirm both are in good standing with the Home Office and MHRA before signing a supply agreement.
Step 2: Prepare your documentation package. Assemble your Health Canada GMP certificate, GACP certification if held, COA from an ISO 17025 lab, batch traceability records, and product information sheet. Gaps in this package are the leading cause of LNOI refusals.
Step 3: Your UK partner obtains the MHRA Letter of No Objection to Import. Allow four to eight weeks. Don't treat this as a formality. The MHRA will flag incomplete or inconsistent documentation.
Step 4: Apply for your Health Canada export permit. Once the LNOI is in hand, your UK partner applies for the UK import licence through the Home Office's National Drug Control System (NDS) portal. Simultaneously, you apply for your per-shipment export permit from Health Canada under the Cannabis Regulations. Health Canada typically processes these in 30 days.
Step 5: The UK import licence is issued. Import licences are valid for three months. Don't let it lapse.
Step 6: Ship, clear customs, deliver to the UK distributor's Schedule 2-compliant storage facility. MHRA border checks can delay clearance if documentation is incomplete or doesn't match the shipment. Include all paired documents.
For detail on the Canadian side of this process, see our guide to the Health Canada Cannabis Export Permit Process.
How Health Canada GMP is recognised in the UK
Canadian LPs frequently ask whether you'll need a separate EU-GMP certificate to supply the UK. You don't. The MHRA recognises Health Canada GMP as an equivalent standard for CBPM importation. A valid Health Canada GMP certificate covering your manufacturing activities is sufficient for MHRA review.
This is a meaningful difference from the German channel, which has historically required EU-GMP certification or a formal equivalence recognition for the Bundesopiumstelle (BfArM) process. For a detailed look at what German importers require from Canadian suppliers, see our guide on what German cannabis importers look for. The MHRA's recognition of Health Canada GMP makes the UK a practical near-term option for Canadian LPs who already hold strong domestic compliance credentials.
There are conditions. The MHRA will verify your certificate is current, covers the specific sites and activities in the shipment, and matches the product details in the documentation package. Expired or scope-limited GMP certificates are a common cause of LNOI refusals. That's a costly delay on a time-limited import licence, so confirm your GMP scope before submitting the package.
For a detailed comparison of the two standards, see our article on EU-GMP vs Health Canada GMP for Cannabis Export.
Frequently Asked Questions
Does Health Canada GMP certification satisfy UK MHRA import requirements?
Yes. The MHRA recognises Health Canada GMP as an equivalent standard for CBPM importation into the UK. A Canadian LP holding a current Health Canada GMP certificate covering the relevant manufacturing activities can supply the UK channel without requiring a separate EU-GMP certificate.
Who holds the import licence: the Canadian exporter or the UK distributor?
The UK distributor holds both the Controlled Drugs domestic licence and the per-shipment import licence issued by the Home Office. The Canadian exporter holds the Health Canada export permit. Both licences are required for a consignment to move legally.
How long does a UK import licence take to obtain?
The MHRA Letter of No Objection to Import (LNOI) takes approximately four to eight weeks from submission of a complete documentation package. The Home Office import licence is then issued through the NDS portal, typically within a few weeks. Total lead time from documentation submission to a valid import licence is commonly 10 to 14 weeks for a first shipment.
Is GACP certification required to export cannabis to the UK?
GACP certification is the preferred standard, and the MHRA expects cultivation to meet GACP principles. The MHRA doesn't mandate a formal GACP certificate in all cases, but holding one strengthens your documentation package and reduces the risk of an MHRA hold.
What is the most common reason MHRA holds a shipment at the UK border?
Incomplete COA panel data is consistently cited as a leading cause of MHRA holds. COAs must cover potency, residual solvents, microbials, heavy metals, pesticides, and water activity. Missing a required panel, submitting a COA from a non-ISO 17025 lab, or providing a COA that doesn't match the specific batch can all trigger a hold or refusal.
